Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)
WATCH-TMVR (Watchman for Patients with Atrial Fibrillation Undergoing Transcatheter Mitral Valve) Clinical Trial have the main objective to assess the feasibility of combining clinically indicated MitraClip TMVR and Watchman LAAO in one setting.Mayo Clinic will be the data coordinating center for this trial, which will include up to 3 sites.
• Men and Women ≥ 18 years of age;
• The patient has severe symptomatic mitral regurgitation meet criteria for the commercially available MitraClip;
• The patient also has documented paroxysmal, persistent, or permanent atrial fibrillation AND The patient meets the WATCHMAN labeling guidelines;
• The patient is eligible for short-term oral anticoagulation therapy with Warfarin or a direct oral anticoagulant;
• The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial;
• The patient is able and willing to return for required follow-up visits.